TARPON SPRINGS, Fla., June 2, 2025 - Allarity Therapeutics, Inc. (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company, has announced the enrollment of the first patient in its new Phase 2 clinical trial protocol for stenoparib. This trial focuses on the treatment of advanced, platinum-resistant or platinum-ineligible ovarian cancer. The study aims to evaluate the overall efficacy and safety of stenoparib, a dual PARP and WNT pathway inhibitor, and to enhance understanding of its modulation of the WNT signaling pathway, which is significant in the progression of ovarian and other cancers. The trial is structured to explore optimal dosing levels and aligns with the FDA's Project Optimus initiative, potentially informing future pivotal registration trials. Allarity plans to expedite approval processes for stenoparib and its DRP companion diagnostic by leveraging multiple regulatory pathways. The company anticipates significant clinical data by late summer 2026.